Hello and welcome to the details of Czech health ministry recommends use of Lilly and Regeneron Covid-19 antibody therapies and now with the details
PRAGUE, Feb 8 — The Czech Health Ministry will recommend the use of Covid-19 therapies that contain casirivimab/imdevimab and bamlavinimab antibodies ahead of standard approval, the ministry said today.
Both therapies are being reviewed by the European Medicines Agency (EMA), the agency said last week.
The Czech Republic has been among the European countries worst hit by the current wave of the coronavirus pandemic, with the number of new infections per 100,000 people higher only in Portugal and Spain, according to data from the European Centre for Disease Prevention and Control (ECDC) released last week.
“The Ministry will recommend distribution and use of unregistered treatments which contain casirivimab/imdevimab and bamlavinimab antibodies,” the ministry said.
It said it would wait for an expert opinion from the national drug agency SUKL before issuing a final ruling.
The former points to Regeneron’s cocktail of casirivimab and imdevimab, which was authorised for emergency use in the United States in November, and was given to then US. president Donald Trump during his Covid-19 infection.
The latter, Eli Lilly’s combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalisation and death in Covid-19 patients by 70 per cent, data from a late-stage trial showed in January.
Czechs should receive the first 500 doses of the therapy in February, Prime Minister Andrej Babis said last Friday.
The ministry said the treatment would be beneficial mainly for patients with high risk of deterioration, such as people who had received organ transplants. — Reuters
These were the details of the news Czech health ministry recommends use of Lilly and Regeneron Covid-19 antibody therapies for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.